Form 4: ARS Pharmaceuticals Director Pratik Shah Granted 30,000 Stock Options

ARS Pharmaceuticals, Inc. Director Pratik Shah was granted 30,000 stock options with an exercise price of $17.26, vesting by June 25, 2026, or the 2026 annual meeting.

Summary

• Pratik Shah, a Director of ARS Pharmaceuticals, Inc. (SPRY), was granted 30,000 stock options.
• The transaction date for this grant was June 25, 2025.
• The exercise price for these stock options is $17.26 per share.
• The options will vest in full on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 24, 2035.
• Following this transaction, Pratik Shah beneficially owns 30,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholders, indicating a commitment to long-term value creation. It is not a major market-moving event but reflects standard corporate governance.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The options were granted at an exercise price of $17.26, indicating a potential future upside for the director if the stock price appreciates.

Negatives

• No immediate negatives are apparent from this routine insider compensation filing.

Risks

• The value of the stock options is dependent on the future performance of ARS Pharmaceuticals' stock price; if the stock price does not exceed the exercise price, the options may expire worthless.
• The exact vesting date is contingent on the 2026 annual meeting date, which has not yet been set by the Board of Directors, introducing a minor uncertainty regarding the precise vesting timeline.

Future Outlook

The stock options granted to Director Pratik Shah are set to vest in full on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, providing a future incentive for the director.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industry, serving as a common form of equity compensation to attract, retain, and incentivize key personnel by aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• The granting of stock options to directors is a widely accepted compensation practice across various industries, including pharmaceuticals, to align management incentives with shareholder returns.
• Without specific details on ARS Pharmaceuticals' peer group compensation policies or the director's overall compensation package, a direct quantitative comparison to industry benchmarks for the size or terms of this specific grant is not feasible from this document alone.

Related Party Transactions

• The grant of 30,000 stock options to Pratik Shah, a Director of ARS Pharmaceuticals, Inc., constitutes a related party transaction, as it involves compensation provided by the company to an insider. This is a common and disclosed practice for executive and director compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The director's compensation structure is enhanced, providing a long-term incentive.

Next Steps

• The stock options will vest on the earlier of June 25, 2026, or the date of ARS Pharmaceuticals' 2026 annual meeting of stockholders.
• Following vesting, Pratik Shah will have the right to exercise these options at $17.26 per share until their expiration on June 24, 2035.

Key Dates

Keywords

ARS Pharmaceuticals, SPRY, Stock Option Grant, Insider Transaction, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation